6533b838fe1ef96bd12a3da3
RESEARCH PRODUCT
Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure.
Pilar MerlosVicent BodíFrancisco J. ChorroVicente Bertomeu-gonzalezEduardo NúñezGema MiñanaPau LlàcerSilvia VenturaPatricia PalauGregg C. FonarowJulio NúñezJuan Sanchissubject
Malemedicine.medical_specialtymedicine.drug_classRenal functionGastroenterologyRisk AssessmentLoop diureticsBlood Urea NitrogenCohort StudiesSodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinemedicineHumansProspective StudiesMortalityProspective cohort studyBlood urea nitrogenAgedAged 80 and overHeart Failurebusiness.industryHazard ratioFurosemideAcute heart failureLoop diureticMiddle Agedmedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complicationsHospitalizationBlood urea nitrogenEndocrinologyCarbohydrate antigen 125Heart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up Studiesdescription
Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure- tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs following a hospitalization for acute heart failure (AHF). Methods and results We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+12 h after admission. HDLDs (≥120 mg/day in furosemide equivalent dose) were interacted to a four-level variable according to CA125 (.35 U/mL) and BUN (above the median), and related to all-cause mortality. At a median follow-up of 21 months, 561 (40.4%) patients died. The use of HDLDs was independently associated with increased mortality (hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.01-1.50), but this association was not homoge- neous across CA125-BUN categories (P for interaction ,0.001). In patients with normal CA125, use of HDLDs was associated with high mortality if BUN was above the median (HR 2.29, 95% 1.51-3.46), but not in those with BUN below the median (HR 1.22, 95% CI 0.73-2.04). Conversely, in patients with high CA125, HDLDs showed an association with increased survival if BUN was above the median (HR 0.73, 95% CI 0.55-0.98) but was associated with increased mortality in those with BUN below the median (HR 1.94, 95% CI 1.36-2.76). Conclusion The risk associated with HDLDs in patients after hospitalization for AHF was dependent on the levels of BUN and CA125. The information provided by these two biomarkers may be helpful in tailoring the dose of loop diuretics at discharge for AHF.
year | journal | country | edition | language |
---|---|---|---|---|
2012-01-01 | European journal of heart failure |